首页> 中文期刊>中国医学创新 >新生儿行为神经测定及早期干预在新生儿脑损伤性疾病中的临床应用分析

新生儿行为神经测定及早期干预在新生儿脑损伤性疾病中的临床应用分析

     

摘要

目的:研究新生儿行为神经测定(neonates behavioral nerve assessment,NBNA)及早期干预应用于新生儿脑损伤性疾病的临床价值。方法:选取2012年5月-2014年5月在本院住院的新生儿468例。选取无脑损伤的212例新生儿为正常组,选疑似脑损伤采取早期干预的154例新生儿为观察组,另选疑似脑损伤未采取早期干预的102例新生儿为对照组。比较三组新生儿行为神经评分及后遗症情况。结果:干预前,正常组NBNA评分为(37.85±1.32)分,明显高于观察组的(34.13±1.58)分及对照组的(32.81±1.74)分,比较差异有统计学意义(P<0.05);干预后,观察组NBNA评分为(39.41±1.23)分,明显高于对照组的(36.52±1.87)分,差异有统计学意义(P<0.05);观察组后遗症发生率显著低于对照组(P<0.05)。结论:NBNA可明确了解新生儿行为能力,可及时发现易漏诊的轻微脑损伤及脑细胞发育异常,早期干预可促进新生儿神经系统代偿性的恢复,降低残障发生率,值得临床推广应用。%Objective:To analyze the clinical value of NBNA and early intervention in application of neonatal brain injury disease.Method:468 cases of hospitalization neonates in our hospital were selected from May 2012 to May 2014, 212 cases of non-brain injury neonates were selected as the normal group,154 cases of neonates with suspected brain injury to take early intervention were selected as the observation group,another 102 cases of neonates suspected brain injury not to take early intervention were selected as the control group .The neonates behavior nerve score and sequelae situation were compared in three groups.Result: Before intervention,the normal group of NBNA scores were (37.85±1.32) significantly higher than the observation group of (34.13±1.58) scores and control group of (32.81±1.74) scores ,the differences were statistically significant(P<0.05);after intervention, the observation group of NBNA scores were (39.41±1.23) significantly higher than the control group of (36.52±1.87)scores, the difference was statistically significant (P<0.05); the observation group of sequelae incidence was significantly lower than the control group, the difference was statistically significant (P<0.05).Conclusion:NBNA can understanding the behavior and capacity of neonatal clearly and find mild brain injury and brain cell abnormalities that clinically easily missed in time,early intervention can improve nervous system compensatory restoration,induce the incidence of disability,has worthy of clinical promotion and application.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号